

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/533,381 03/22/2000		Nicola Fanto	2801-14	8341
75	590 12/31/2002			
Nixon & Vano		EXAMINER		
1100 North Gle 8th Floor	be Rd	BARTS, SAMUEL A		
Arlington, VA	22201-4714	ART UNIT	PAPER NUMBER	
			1621 DATE MAILED: 12/31/2002	22

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	on No	Applicant(s)					
Office Action Summary		''							
		09/533,38		FANTO ET AL.					
	Office Action Guilliary	Examiner		Art Unit					
	The MAILING DATE of this communication	Samuel A	<u> </u>	1621	dross				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
THE - Exte after - If the - If NO - Failt - Any	MAILING DATE OF THIS COMMUNICATION MAILING DATE OF THIS COMMUNICATION MISSION OF THIS COMMUNICATION OF THIS COMMUNICATION OF THE SIX (6) MONTHS from the mailing date of this communication of period for reply specified above is less than thirty (30) days, a period for reply is specified above, the maximum statutory per ure to reply within the set or extended period for reply will, by stareply received by the Office later than three months after the meet patent term adjustment. See 37 CFR 1.704(b).	N. R 1.136(a). In no ever reply within the state riod will apply and wi atute, cause the app	ent, however, may a reply be tilutory minimum of thirty (30) day II expire SIX (6) MONTHS from lication to become ABANDONE	mely filed ys will be considered time the mailing date of this of ED (35 U.S.C. § 133).	ly. communication.				
1)	Responsive to communication(s) filed on 2	26 Sentember	2002						
2a)□		This action is							
3)	Since this application is in condition for allo			rosecution as to th	ne merits is				
,—	closed in accordance with the practice und ion of Claims								
4)🖂	Claim(s) 8-11 is/are pending in the applicat	tion.							
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)🖂	5)⊠ Claim(s) <u>10</u> is/are allowed.								
6)⊠	6)⊠ Claim(s) <u>8,9 and 11</u> is/are rejected.								
7)	Claim(s) is/are objected to.								
•	Claim(s) are subject to restriction and	d/or election re	equirement.						
	ion Papers								
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.									
Priority under 35 U.S.C. §§ 119 and 120									
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) All b) Some * c) None of:									
۵,	1. Certified copies of the priority docume	ents have bee	n received						
	Certified copies of the priority docume			ion No					
* /	3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.									
	Acknowledgment is made of a claim for dom		•						
Attachmen	) ·								
2) 🔲 Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(			y (PTO-413) Paper No Patent Application (P					

Application/Control Number: 09/533,381 Page 2

Art Unit: 1621

## **DETAILED ACTION**

## Allowable Subject Matter

1. Claim 10 is allowed.

## Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 8, 9 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gaitanopoulous et al (EP 0209275).

Gaitanopoulous et al teach compounds that are very similar to the claimed invention. In the previous office action (paper number 18) it was pointed out numerous compounds that anticipated claims 8, 9 and 11. (i.e. the claimed compounds when  $R=R_1=OH$  or  $OCH_3$  and  $R_2$  is equal to fluoro or chloro) Applicant has amended the claims to obviate the anticipation rejection. However, it is clear from the disclosure of Gaitanopoulous et al that other compounds are contemplated. On page 2 of the specification in Gaitanopoulous et al it is stated "X is hydrogen or halo such as fluoro, bromo or chloro". Therefore, it is clear that Gaitanopoulous et al suggest the halogen bromo.

Application/Control Number: 09/533,381

Art Unit: 1621

The instant claimed invention defines  $R_2$  and halogen. Therefore, the instant invention differs from the prior art as being directed to sub-generic concept. (i.e. the claimed compounds when  $R=R_1=OH$  or  $OCH_3$  and  $R_2$  is equal to bromo). Please note that the compounds of Gaitanopoulous et al are useful as dopaminergic receptor antagonists and that the salts are contemplated (see for example page 2 lines 15-20). Thus, the limitations of claims 9 and 11 are also suggested.

It would have been obvious at the time that applicant's invention was made to have made the compounds wherein  $R=R_1=OH$  or  $OCH_3$  and  $R_2$  is equal to bromo in the invention of Gaitanopoulous et al because the reference suggest such compounds. The compounds fall within the generic teachings and are very structurally similar to exemplified species in the patent. One would have been motivated to make such compounds with a reasonable expectation of using them as dopaminergic receptor antagonist.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Samuel A Barts whose telephone number is 703-308-4630. The examiner can normally be reached on 6:30-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johan Richter can be reached on 308-1235. The fax phone numbers for the organization where this application or proceeding is

Application/Control Number: 09/533,381

Art Unit: 1621

Page 4

assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Samuel A Barts
Primary Examiner

Art Unit 1621

s.b.

December 30, 2002